Mumbai : The National Pharmaceutical Pricing Authority (NPPA) has asked drug manufacturers and marketers to furnish the information relating to price to retailer (PTR) and moving annual turnover (MAT) in value term for about 29 NLEM formulations for the month of March 2021. The information will be used by NPPA for fixing ceiling price of the formulations under provisions of DPCO, 2013.
The formulations include abacavir (60mg tablet), acetylsalicylic acid (effervescent/dispersible/enteric coated 300 mg to 500 mg tablet), acetylsalicylic acid (300 mg to 500 mg tablet), activated charcoal (powder as licensed), calcium carbonate (250 mg tablet), calcium folinate (3mg/ml injection), cloxacillin (125 mg/5 ml oral liquid), cycloserine (125 mg capsule), dapsone (50 mg tablet) and doxycycline (50 mg/ 5 ml dry syrup).
The other formulations are ethionamide (125 mg tablet), ferrous salt (A) + folic acid (B) (20 mg elemental iron (A) + 100 mcg oral liquid), ferrous salts (tablet equivalent to 60 mg of elemental iron), hydroxocobalamin (1 mg/ml injection), iohexol (140 to 350 mg iodine/ml injection), lamivudine (A)+ zidovudine (B) ((30 mg (A)+60 mg (B) tablet), medroxyprogesterone acetate (5 mg tablet), methylthioninium chloride (methylene blue) (10 mg/ml injection), miltefosine (50 mg capsule) and nevirapine (50 mg dispersible tablet).
Besides them, the list of formulations which will be placed under price control include nystatin (100,000 IU pessary) & nystatin (100,000 IU/ml oral liquid), paromomycin (375 mg/ml injection), povidone iodine (5 per cent drops), pyridoxine (50 mg tablet), sodium chloride (3 per cent injection), vitamin A (100000 IU/ml oral liquid) zidovudine (50 mg/ 5 ml oral liquid) and zidovudine (A)+ lamivudine (B)+ nevirapine (C) ((60 mg (A) + 30 mg (B) + 50 mg (C) tablet).
Earlier NPPA had withdrawn ferrous salt (A) + folic acid (B) (20 mg elemental iron (A) + 100 mcg oral liquid) formulation from price control order.
Rashmi Tahiliani, joint director (pricing), NPPA issued an office memorandum in this regard on July 9, 2021. Tahiliani asked the drug manufacturers and marketing firms to furnish the information pertaining to the formulations, their dosage form and strength, brand, pack size, MAT and PTR as on March 2021 in a prescribed format within ten days from the issue of this memorandum.
The NPPA has also directed pharmaceutical organizations– OPPI, IDMA, AISSPMA, FICCI, IPA and FOPE to ask their member companies to furnish the said information to it.
[pdf-embedder url=”https://medicarepharmabusiness.com/wp-content/uploads/2021/07/OM-19697-2016-130721080824.pdf”]
